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Abstract
Purpose To prevent multiple pregnancies the goal of
ovulation induction by gonadotropins is to achieve only
mono-follicular development. The most important issue is
therefore to determine the starting dose. The aim of this
study is to compare three different starting doses of folli-
tropin beta to assess the lowest effective dose.
Methods We evaluated 92 cycles with ovarian stimula-
tion for patients with unexplained infertility, anovulatory
disorder or mild male factor. We prospectively divided
patients into 50, 75 and 100 IU groups based on patients’
response to clomiphene citrate treatment.
Results We performed 87 intrauterine inseminations
(95 % of cycles with ovulation induction). Five cycles
were cancelled. We achieved 15 pregnancies; total preg-
nancy rate was 18 %. Pregnancy rate was 22, 10 and 28 %
in 50, 75 and 100 IU follitropin beta groups. The average
number of follicles was 2.0 ± 0.8, 2.2 ± 1.1 and 2.5 ± 1.8
(ns), total dose of gonadotropins (IU) 483 ± 192,
600 ± 151 and 830 ± 268 (p \ 0.001), respectively. We
observed one case of twins in 75 and 100 IU treatment
group, as well (25 % risk).
Conclusions This study suggests that based on the dose
which was chosen according to clomiphene citrate
response, all treatment regimes were effective for ovulation
induction. 50 IU of follitropin beta daily is the appropriate
starting dose to support ovulation for clomiphene citrate-
sensitive women. The disadvantage may be an increased
risk of cycle cancellation due to low ovarian response.
Daily doses 75 or 100 IU of rFSH increase total con-
sumption of gonadotropins.
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Introduction
For unexplained infertility, mild male factor and anovu-
latory women who fail to ovulate or conceive with
clomiphene citrate, gonadotropin ovulation induction
combined with intrauterine insemination is used as the
second-line therapy [8]. According to the available clinical
studies about 15–20 % of pregnancies are twins and 5 %
triplets or more [8, 17, 25]. Multiple pregnancies represent
a relevant problem with high incidence of perinatal mor-
tality and severe neonatal morbidity [23]. To prevent
multiple pregnancies the goal of ovulation induction by
gonadotropins is to achieve only mono-follicular devel-
opment and ovulation [3, 20, 22]. Low-dose follicle
stimulating hormone (FSH) regimens have succeeded in
reducing the rate of multiple pregnancies to 2–6 % and
the rate of ovarian hyperstimulation syndrome (OHSS), as
well [23].
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The aim of ovarian stimulation is to reach, but not
exceeding, the threshold level of FSH [14]. In case of
inappropriate ovarian response it is necessary to adjust the
dose of FSH. Hugues in Ref. [15] concluded that ‘the
choice of the FSH starting dose and the modality of sub-
sequent dose adjustments are critical in controlling the risk
of overstimulation’.
We hypothesized that starting dose 75 or 100 IU of
recombinant follicle stimulating hormone (rFSH) compar-
ing with the starting dose 50 IU of rFSH increases expected
pregnancy rate due to achievement of higher number of
follicles and reduction of the risk of cycle cancellation due
to low ovarian response. On the other hand we expected
mild increase multiple pregnancy rate and the risk of cycle
cancellation due to high response.
The objective of the study was to determine the effect of
different follitropin beta dose (50, 75 and 100 IU daily) on
follicular development, thickness of the endometrium at
the time of human chorionic gonadotropin (hCG) admin-
istration, total consumption of gonadotropins per cycle,
pregnancy rate, risk of multiple pregnancy and the risk of
OHSS.
Materials and methods
Between March 2005 and June 2006 women with a history
of infertility signed informed consent and were recruited
for this prospective study. Inclusion criteria were as fol-
lows: infertility at least 1 year, patients at least 18 years of
age but not [38 years, BMI between 18 and 30 kg/m2,
basal serum FSH and luteinizing hormone (LH) B10 IU/l,
normal uterine cavity, at least one patent Fallopian tube
assessed by hysterosalpingography or laparoscopy with
chromosalpingography, history of clomiphene citrate
therapy and sperm count after swim-up C5 million/ml.
Based on patients history of response for clomiphene
citrate treatment we divided the patients into 50, 75 and
100 IU follitropin beta group (the patients with proved
response to clomiphene citrate one tablet daily were allo-
cated into 50 IU follitropin beta group, the women with no
response to clomiphene citrate one tablet daily but proved
response to two tablets daily were enrolled into 75 IU fol-
litropin beta group and finally the patients with proved
response to clomiphene citrate three tablet daily were put
into 100 IU follitropin beta group). We started administra-
tion of 50, 75 or 100 IU follitropin beta subcutaneously on
day 3, patients underwent a transvaginal ultrasonography on
day 9 (Toshiba Famio with a 7.5 MHz probe) and if nec-
essary we adjusted the gonadotropin dose (if we observed
follicles B12 mm in diameter than we increased the FSH
dose by 25 IU). When at least one follicle achieved 18 mm
in diameter and endometrium was at least 8 mm thick we
administrated hCG 5,000 IU subcutaneously and after
36–38 h we performed intrauterine insemination with luteal
phase support by micronised progesterone 200 mg daily
vaginally. To minimize the risk of a multiple pregnancy,
hCG was withheld if more than four follicles 14 mm in
diameter were seen. The couple was advised not to have
unprotected intercourse.
Statistical analysis was performed by v2 test and
ANOVA (GraphPad Software). A value of p \ 0.05 was
considered statistically significant.
Results
We evaluated a total number of 92 ovarian stimulations for
couples with unexplained infertility, anovulatory disorder
or mild male factor. We performed 87 intrauterine insem-
inations (95 % of cycles with ovulation induction).
Baseline and hormonal characteristics of patients are
summarized in Table 1. No significant differences
according to study groups were documented. We noted
some differences (but not significant) in the frequency of
patients with ovulatory disorders and mild male factor.
Patients with ovulatory disorders were more frequent in the
100 IU group and patients with mild male factor in the 50
and 75 IU groups. Cycle characteristics according to
treatment group are described in Table 2. No significant
differences were observed in the need to adjust the initial
gonadotropin dose. Total consumption of rFSH was sig-
nificantly higher in women receiving starting dose 100 and
75 IU daily compared with starting dose 50 IU daily
(p \ 0.001). There was a slight, but not a significant, dif-
ference in number of follicles and thickness of








Age (years)a 30 ± 3 30 ± 3 29 ± 4 ns
Primary infertility
(%)b
25 (71) 27 (65) 8 (58) ns
Duration of infertility
(years)a
1.5 ± 0.7 1.4 ± 0.7 1.9 ± 1.1 ns
Cause of infertilityb ns
Unexplained (%) 1 (3) 1 (2) 0 (0)
Ovulatory
disorder (%)
13 (35) 12 (28) 8 (57)
Mild male factor (%) 21 (60) 29 (69) 5 (36)
Endometriosis (%) 0 (0) 0 (0) 1 (7)
FSH (IU)a 6.8 ± 1.5 6.6 ± 1.5 6.8 ± 1.2 ns
LH (IU)a 5.6 ± 2.0 5.7 ± 2.4 7.1 ± 2.3 ns
a Values are expressed as mean ± SD, ANOVA
b The frequency distribution analysis v2 test
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endometrium between groups. Duration of treatment does
not differ in the study groups. Five cycles were cancelled
(8 %). Reasons for cycle cancellation are presented in
Table 3. Table 4 shows outcome of treatment. Clinical
pregnancy rate per completed cycle was 22, 10 and 28 %,
respectively. No significant differences according to study
group were documented. Total clinical pregnancy rate was
17 % (15 pregnancies in 87 completed cycles). Spontane-
ous abortion occurs in one case. We observed one case of
twins in 75 and 100 IU treatment group, as well (25 % risk
of multiple pregnancy). None of the patients developed
ovarian hyperstimulation syndrome.
Discussion
Intrauterine insemination is recommended as the first-line
treatment for couples with unexplained infertility or male
subfertility [6, 9, 17, 27]. The expected pregnancy rate of
intrauterine inseminations in natural cycles is about 6.3 %
[24]. Ovulation induction increases the number of available
oocytes and pregnancy rate [24, 26, 27]. Costellos’s meta-
analysis of randomized controlled trials [7] and Arici’s
study [1] revealed increasing pregnancy rate with ovulation
induction by clomiphene citrate than natural cycle com-
bined with intrauterine insemination. Clomiphene citrate is
recommended as the initial treatment for women with
unexplained infertility, mild male subfertility and WHO
group II anovulation [9, 20]. This treatment achieves
ovulation in approximately 70 % of patients and pregnancy
within 6 months in 35 % [11, 18]. Multifollicular growth
explains high rate of multiple pregnancies after clomiphene
citrate therapy—20 % risk of twins and about 5 % risk of
triplets [8].
Costellos’s metaanalysis of randomized controlled trials
[7] and Balash’s study [2] confirm increasing pregnancy
rate with ovulation induction by gonadotropins than clo-
miphene citrate combined with intrauterine insemination.
Randomized controlled trial [5] demonstrated that ovula-
tion occurred in 70 % in the recombinant FSH group versus
66 % in the urinary FSH group, total dose of gonadotropins
was 750 IU versus 1,035 IU and duration of treatment
(10 days vs. 13 days), respectively. Other studies [10, 12,
13] compared recombinant gonadotropins versus urinary
ones for ovulation induction combined with intrauterine
insemination. In randomized study [10] Demirol proved
pregnancy rate 25.9 % versus 13.8 %, respectively. The
advantage of recombinant FSH is availability of small
dose—50 IU daily—for self subcutaneous administration
and safe profile of treatment. Based on studies [16, 22],
which compared different gonadotropin preparations in
intrauterine insemination, recombinant FSHs result in a
better outcome for unexplained infertility than urinary
gonadotropins. The daily doses of recombinant FSH from
50 to 100 IU were used [16].










7 (22) 4 (10) 4 (28) ns
Abortions n (%)a 1 (3) 0 0 ns
Ongoing pregnancy
rate n (%)a
6 (19) 4 (10) 4 (28) ns
Twins n (%)a 0 1 (25) 1 (25) ns
a The frequency distribution analysis was performed by v2 test



























483 ± 192 600 ± 151 830 ± 268 p \ 0.001
Duration of
cycle (days)b







a The frequency distribution analysis v2 test
b Values are expressed as mean ± SD, ANOVA










4 (11) 1 (2) 0 ns
Reasons for the cycle cancellation:
Low ovarian response
n (%)a
3 (8) 0 0 ns
More than 4 follicles
14 mm n (%)a
0 1 (2) 0 ns
The follicle at side of
salpingectomy n (%)a
1 (3) 0 0 ns
a The frequency distribution analysis was performed by v2 test
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For unovulatory woman with PCO syndrome treated with
a starting dose of 50 IU rFSH there is necessary to increase a
dose after 7–14 days of drug administration unless follicles
are less than 12 mm in diameter [19]. A study conducted by
Leader [18] compared dose increment 25 IU versus 50 IU.
Similar with our results the 25-IU group had a higher inci-
dence of mono-follicular growth (41.3 % vs. 21.8 %),
ovulation (81.3 % vs. 60.3 %), lower total cumulative
gonadotropins dose (887 IU vs. 984 IU). A dose increment
50 IU increases risk of overresponse from 5 to 20 %. About
5 % cycles are cancelled due to low ovarian response.
Several randomized studies are available for unovulatory
women with PCO syndrome, seeking the dose of gonado-
tropins. Both randomized studies [15, 18] conclude that a
starting dose of 50 IU recombinant FSH is adequate. Current
study with low dose step up protocol [3] demonstrated 90 %
ovulation rate, 15 % pregnancy rate, one case of OHSS
(1.3 %) and risk of multiple pregnancy 25 %.
For women treated for unexplained infertility or mild
male factor who fail to ovulate or conceive with clomi-
phene citrate, non-randomized Calaf’s study [4] suggested
starting dose 50 IU recombinant FSH daily. One retro-
spective study [21] compared 50 and 75 IU of recombinant
FSH combined with intrauterine insemination for unex-
plained infertility and achieved pregnancy rate 10 %. The
study concluded that minimal FSH stimulation (up to two
follicles) combined with intrauterine insemination cycle
may reduce the rates of twins and high-order multiple
pregnancies without affecting overall pregnancy rates.
We can explain the fact that study [9] observed preg-
nancy rate 34.3 % in the gonadotropin group compared
clomiphene citrate group for unexplained and male sub-
fertility. This pregnancy rate was higher than in our study.
Women in our study were treated with clomiphene citrate
for 3 months before study occurred with additional preg-
nancy rate 12 % [24]. Our pregnancy rate was higher
(17 % vs. 12 %) and risk of cycle cancellation due to low
ovarian response lower (8 % vs. 13.2 %) compared with
another study [8].
The limitation of our study should be number of cases in
groups. Despite this fact we proved significant differences
in total consumption of gonadotropins between groups.
Moreover, we intentionally did not compare other available
prognostic markers (for e.g. FSH level, anti-Mullerian
hormone (AMH), inhibin B etc.) with results of our study.
Another trial (probably multicenter) is necessary for com-
paring all parameters in the future.
In summary, our work aims to assess the lowest effec-
tive gonadotropin dose and to find simple and easy to
measure prognostic value for later response to ovarian
stimulation combined with intrauterine insemination. We
hope that results of our study may be helpful in tailoring
treatment to individual patients.
Conclusions
This study suggests that based on the dose which was
chosen according to clomiphene citrate response, all
treatment regimes were effective for ovulation induction
combined with intrauterine insemination. 50 IU of folli-
tropin beta daily is the appropriate starting dose to support
ovulation for clomiphene citrate sensitive women. The
disadvantage may be an increased risk of cycle cancellation
due to low ovarian response. Daily doses 75 or 100 IU of
rFSH increase total consumption of gonadotropins. The
choice of correct gonadotropin starting dose and its
adjustment are important steps to minimize the risk of
multi-follicular development, multiple pregnancy and
OHSS.
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